Literature DB >> 16880104

Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study.

Vitantonio Di Bello1, Ferruccio Santini, Andrea Di Cori, Andrea Pucci, Caterina Palagi, Maria Grazia Delle Donne, Paola Fierabracci, Alessandro Marsili, Enrica Talini, Monica Giannetti, Ombretta Biadi, Alberto Balbarini, Mario Mariani, Aldo Pinchera.   

Abstract

Obesity is a well-established risk factor for congestive heart failure. Evidence has been provided indicating that insulin resistance could be the mediator between obesity and congestive heart failure, but the pathogenic mechanisms leading to myocardial alterations remain unclear. The aim of this study was to investigate, by ultrasonic integrated backscatter (IBS) analysis, subclinical alterations of left ventricular (LV) structure and function in severe obesity. Sixty consecutive, severely obese people, who were otherwise healthy (15 men, 45 women; mean age +/- SD = 31.8 +/- 7 years), were enrolled. A total of 48 sex- and age-matched nonobese healthy participants were recruited as control subjects. All participants underwent conventional 2-dimensional color Doppler echocardiography, pulsed wave Doppler tissue imaging at mitral annulus level, and IBS. The homeostasis model assessment insulin resistance index was used to assess insulin resistance; the index values in the obese group were significantly higher (mean +/- SD = 4.9 +/- 1.4) than in the control group (0.92 +/- 0.5, P < .0001). Obese patients had a greater LV mass index by height (58.5 +/- 14 g/m(2.7)) than did control subjects (37 +/- 8 g/m(2.7), P < .0001) because of compensation response to volume overload caused by a greater cardiac output (P < .02). Preload reserve was increased in obese patients, as demonstrated by the significant increase in left atrial dimension (P < .0001). This volumetric increase activated the Frank-Starling mechanism, and determined a significantly higher LV ejection fraction (P < .03) in obese patients as compared with control subjects. A slightly reduced LV diastolic function was demonstrated in obese patients (transmitral early to late peak diastolic transmitral flow velocities ratio = 1.1 +/- 0.7) as compared with control subjects (1.5 +/- 0.5, P < .02). Pulsed wave Doppler tissue imaging showed an impairment of diastolic LV longitudinal function and increased LV diastolic filling pressure. The IBS values at septum level, indexed by pericardium interface, were significantly higher for septum in the obese group (57.8 +/- 8%) than in the control group (42.3 +/- 9%, P < .0001). Additional IBS alterations were observed in the obese group, with a significantly lower cyclic variation index both at septum (P < .0001) and at posterior wall (P < .001) levels. A significant association was found between insulin resistance index and both the IBS index of myocardial reflectivity at septum level (expression of increased myocardial collagen content) or LV mass. In conclusion, this study demonstrates that obese patients exhibit myocardial structural and functional alterations related to insulin resistance and to LV volume overload, which could be considered the very early stage of incipient obesity cardiomyopathy.

Entities:  

Mesh:

Year:  2006        PMID: 16880104     DOI: 10.1016/j.echo.2006.03.033

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  27 in total

1.  Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction.

Authors:  Asli F Ceylan-Isik; Nair Sreejayan; Jun Ren
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

2.  Left ventricle diastolic dysfunction in obese patients with newly diagnosed arterial hypertension.

Authors:  Viktor Persic; Alen Ruzic; Bojan Miletic; Sanja Balen; Zeljko Jovanovic; Aleksandar Vcev; Sanjin Racki; Bozidar Vujicic
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

3.  Asymmetric left ventricular hypertrophy associated with morbid obesity mimicking familial hypertrophic cardiomyopathy.

Authors:  Raymond Ching-Chiew Wong; Kong Bing Tan
Journal:  Singapore Med J       Date:  2014-12       Impact factor: 1.858

4.  Impact of Body Mass Index on Left Ventricular Function.

Authors:  D S Chadha; A Swamy; S K Malani; R K Ganjoo; O P Mathew
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  The importance of speckle tracking echocardiography in the early detection of left ventricular dysfunction in patients with polycystic ovary syndrome.

Authors:  Selami Demirelli; Husnu Degirmenci; Emrah Ermis; Sinan Inci; Gokay Nar; Mehmet Emin Ayhan; Serdar Fırtına; Hikmet Hamur; Senay Arikan Durmaz
Journal:  Bosn J Basic Med Sci       Date:  2015-10-19       Impact factor: 3.363

6.  Effect of patient and hospital characteristics on outcomes of elective ventral hernia repair in the United States.

Authors:  Y W Novitsky; S B Orenstein
Journal:  Hernia       Date:  2013-04-24       Impact factor: 4.739

7.  Obesity and preclinical changes of cardiac geometry and function.

Authors:  Joong Kyung Sung; Jang-Young Kim
Journal:  Korean Circ J       Date:  2010-02-23       Impact factor: 3.243

8.  Relationship between adiponectin and left atrium size in uncomplicated obese patients: adiponectin, a link between fat and heart.

Authors:  Juan Ybarra; Eugenia Resmini; Francesc Planas; Francesc Navarro-López; Susan Webb; Jose Maria Pou; Alicia Santos; Carlos Ballesta-López
Journal:  Obes Surg       Date:  2009-07-23       Impact factor: 4.129

9.  Quantitative analysis of the magnitude and time delay of cyclic variation of myocardial backscatter from asymptomatic type 2 diabetes mellitus subjects.

Authors:  Allyson A Gibson; Jean E Schaffer; Linda R Peterson; Kyle R Bilhorn; Karla M Robert; Troy A Haider; Marsha S Farmer; Mark R Holland; James G Miller
Journal:  Ultrasound Med Biol       Date:  2009-07-17       Impact factor: 2.998

Review 10.  Nonalcoholic fatty liver disease as a multi-systemic disease.

Authors:  Hakan Fotbolcu; Elçin Zorlu
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.